Pirenzepine

Pirenzepine

Clinical data
AHFS/Drugs.com	Monograph
ATC code	A02BX03 (WHO)
Identifiers
IUPAC name 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
CAS Number	28797-61-7 Y
PubChem (CID)	4848
IUPHAR/BPS	328
DrugBank	DB00670 Y
ChemSpider	4682 Y
UNII	3G0285N20N Y
KEGG	D08389 Y
ChEBI	CHEBI:8247 Y
ChEMBL	CHEMBL9967 Y
ECHA InfoCard	100.044.739
Chemical and physical data
Formula	C19H21N5O2
Molar mass	351.403 g/mol
3D model (Jmol)	Interactive image
SMILES O=C3c1ccccc1N(C(=O)CN2CCN(C)CC2)c4ncccc4N3
InChI InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) Y Key:RMHMFHUVIITRHF-UHFFFAOYSA-N Y

Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation. It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier.

Pirenzepine has been investigated for use in myopia control.

It promotes the homodimerization or oligomerisation of M1 receptors.